EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products, announced that it has published a scientific white paper (view the paper here) clarifying the relationship between the company’s two related categories of products and explaining how each targets pathogens and inflammation.
Help employers find you! Check out all the jobs and post your resume.
